Dr. Langer is the David H. Koch Institute Professor at MIT. Serial entrepreneur and founder of over 20 companies, he has received the National Medal of Science, Charles Stark Draper Prize, Albany Medical Center Prize and the Lemelson-MIT prize. Dr. Langer is one of the very few individuals ever elected to the Institute of Medicine, the National Academy of Engineering, and the National Academy of Sciences. He is the most cited engineer in history.
Robert received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering.
Dr. Clark is the Director of the Clinical Trials Core, Dana-Farber/Harvard Cancer Care, Massachusetts General Hospital; and an Associate Professor, Medicine, Harvard Medical School. His research efforts have focused on evaluation of new agents in phase I, pilot and early phase II trials to treat malignancies, especially pancreatic and other gastrointestinal cancers.
Jeff has worked closely with radiation oncologists and surgeons in designing and performing clinical trials evaluating new approaches aimed at enhancing therapeutic efficacy in this setting.
Darshana Zaveri is a Partner and a member of Catalyst Health Ventures' investment committee. Darshana brings over a decade of experience in the health care and Life Science Industries. Prior to Catalyst, she was an Investigator at Vertex Pharmaceuticals and an integral part of the drug development programs in oncology, metabolic disease, and immunology. She has authored several publications and currently serves as a Catalyst of the Deshpande Center for Technological Innovation at MIT.
Darshana received an MPA from Harvard University, a Master in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.
Patrick Rivelli has been a medical device entrepreneur and investor for over 25 years. He is currently President and CEO of Sonogenix, Inc., a clinical stage medical device company; as well as Co-Director and Life Sciences Track Lead at MIT Angels, an angel investor group. He was previously founder and CEO of Smart Therapeutics (acquired by Boston Scientific) & Bioabsorbable Therapeutics (acquired by Multi Cell Corporation).
Patrick holds a BA in Economics from Harvard University and a MS in Management from the MIT Sloan School. He also holds 9 issued patents.
Stephanie Fohn is a serial entrepreneur and CEO with an impressive track record of success in growing early stage start-ups to successful exits. Most recently, she was CEO of Remotium, Inc., a provider of mobile virtualization solutions (acquired by Avast Software). Previously, she was CEO of WhiteHat Security, a global leader in SaaS application security testing, and President and COO of SecurityFocus (acquired by Symantec). She is currently an investor and advisor to a number of firms, including PeakSpan Capital.
Stephanie holds BAs in Business and Psychology from University of Washington and an MS in Management from the MIT Sloan School.